Article
Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.
Future oncology (London, England) - 1 Jun 2021
Aguado-Fraile Elia, Tassinari Ania, Ishii Yuko, Sigel Carlie, Lowery Maeve A, Goyal Lipika, Gliser Camelia, Jiang Liewen, Pandya Shuchi S, Wu Bin, Bardeesy Nabeel, Choe Sung, Deshpande Vikram
Abstract excerpt
Background: IDH1 mutations occur in approximately 13% of intrahepatic cholangiocarcinomas (IHCCs). The oral, targeted, mutant IDH1 (mIDH1) inhibitor ivosidenib (AG-120) suppresses production of the oncometabolite D-2-hydroxyglutarate, promoting disease stabilization and improved progression-free survival (PFS) in mIDH1 IHCC. Materials & methods: Harnessing matched baseline and on-treatment biopsies, we...
Topics
Join the communities discussing this publication.